A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Inclusion Criteria

• •Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:
• •* Absence of changes in medical therapy within 60 days of Visit 1 due to treatment failure or toxicity.
• •* Absence of serious or significant medical events within 30 days of Visit 1.
• •* Absence of known, current, and life-limiting diagnoses which, in the opinion of the Investigator, would make completion of the protocol unlikely.
• •Participant has received a single dose of Arexvy or Abrysvo at least 12 months prior to Visit 1. Participants must provide proof of RSV vaccination status (including brand and date received) prior to enrollment.